What Doloproct 0.1% + 2% Treats: Main Uses and Benefits

Treating Acute Pain and Sensory Distress in Anorectal Conditions

This medication is applied in clinical settings that involve acute or unstable symptom patterns, primarily used for managing symptoms related to physical discomfort, such as pain, burning, and persistent itching (pruritus). The therapeutic benefit may be part of symptomatic management for conditions involving inflammatory or irritative processes, such as haemorrhoidal disease, non-infected proctitis, and anal eczema. The preparation is intended for the local treatment of inflammatory processes in the lower rectum and around the anus, as well as for anal eczemas.

Comprehensive Management for Dual Symptom Patterns

This approach is applicable within clinical settings that involve acute or disruptive symptom patterns, because it helps address symptom clusters that may become intense or disruptive by tackling both inflammation and pain simultaneously. The preparation contributes to easing the overall symptom load and may help patients cope more steadily when symptoms are more noticeable, providing supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Relief for Acute Pain and Inflammation

Regulatory References

1. BPOM Regulatory Overview

Who Can and Cannot Use Doloproct 0.1% + 2%

Population eligibility for Doloproct 0.1% + 2% is strictly defined by regulatory documents, focusing on patient status, age, and physiological condition.

---

Absolute Contraindications

The medicine is contraindicated for individuals with a known hypersensitivity to Fluocortolone, Lidocaine Hydrochloride, or any excipients. Use must be avoided if active viral diseases (e.g., Herpes Zoster, Chickenpox), tuberculous, syphilitic, primary bacterial, or fungal infections are present in the area to be treated, as the corticosteroid component may mask or spread the infection.

---

Eligibility by Age and Status

Population Group	Regulatory Status
Adults (General)	Authorized for use (primary eligible population).
Children & Adolescents (Under 18)	Not recommended; safety and efficacy are not established by regulatory bodies.
First Trimester Pregnancy	Not recommended.
Second/Third Trimester Pregnancy	Conditional Use (only if benefit outweighs risk); prolonged or excessive use must be avoided.
Hepatic or Renal Impairment	Caution is required due to the systemic metabolism of the Lidocaine component.

---

Treatment duration should not exceed four weeks to limit systemic exposure. Concurrent antimycotic therapy is required if a fungal infection is present.

Interactions with other medicines and products

Doloproct contains the corticosteroid fluocortolone pivalate and the local anesthetic lidocaine hydrochloride. Due to the route of administration, the potential for systemic drug interactions is considered low under recommended usage but increases with extensive use, high dosage, or on damaged mucosa.

---

Corticosteroid Component (Fluocortolone Pivalate)

Concomitant treatment with medications known as strong CYP3A4 inhibitors may increase the systemic exposure of fluocortolone, which is primarily metabolized by the CYP3A4 enzyme. Increased systemic exposure elevates the risk of systemic corticosteroid side effects. Specific strong CYP3A4 inhibitors, such as Ritonavir and Cobicistat, are expected to cause this effect. The combination with such inhibitors should be avoided unless the benefit significantly outweighs the risk, and careful monitoring for signs of systemic corticosteroid effects is necessary.

---

Local Anesthetic Component (Lidocaine Hydrochloride)

If lidocaine is absorbed into the bloodstream in clinically significant amounts, its effects can be additive with other medicines that affect cardiac function. Therefore, systemic absorption may result in an increased risk of adverse effects when administered concomitantly with other anti-arrhythmic medicinal products. Patients receiving anti-arrhythmic therapy should be closely monitored if using this product extensively.

How Doloproct 0.1% + 2% Works

Doloproct 0.1% + 2% combines two active pharmacological agents, Fluocortolone Pivalate and Lidocaine, which modulate distinct biological pathways to achieve a combined local physiological effect. The mechanism involves both systemic anti-inflammatory action and local neural signal blockade.

Glucocorticoid Receptor Modulation (Fluocortolone Pivalate)

Fluocortolone Pivalate functions as a corticosteroid prodrug. After topical administration, the pivalate ester moiety undergoes enzymatic hydrolysis within the tissue, releasing the active molecule, Fluocortolone. This active moiety is a high-affinity agonist for the intracellular Glucocorticoid Receptor (GR). The activated GR translocates to the cell nucleus, where it modulates gene transcription. This process primarily involves the transrepression of pro-inflammatory genes, specifically inhibiting the production of key mediators such as prostaglandins, leukotrienes, and cytokines. The resulting molecular cascade leads to the stabilization of lysosomal membranes, a reduction in the migration of inflammatory cells to the site of application, and decreased capillary permeability, altering localized cellular and vascular responses.

Voltage-Gated Sodium Channel Blockade (Lidocaine)

Lidocaine acts as an amide-class local anesthetic. Its uncharged form passively diffuses across neuronal membranes and then becomes ionized. The resulting cation is an inhibitor that binds reversibly to the voltage-gated sodium channels (VGSCs) located on the internal surface of the neuronal cell membrane. This binding stabilizes the channel in an inactivated state. The resultant blockage of sodium ion influx across the cell membrane prevents the depolarization of the nerve cell. This mechanism stops the propagation of the action potential along the axon, leading to a local interruption of neural signal transmission.

Official Dosing and Administration Guidelines

Doloproct 0.1% + 2% is used for topical rectal administration as a cream or in suppository form, defining a highly localized method of application. The amount applied is a sufficient quantity of cream, typically defined as a finger-tip unit, or one suppository per use.

---

Dosing Frequency and Course Duration

Treatment frequency is based on the stage of symptomatic severity. For the first few days of therapy, especially with acute symptoms, the preparation may be applied up to three times a day (morning, noon, and evening). The standard regimen is generally twice a day, and applications may be reduced to once per day when acute symptoms have abated. The total duration of treatment must not exceed 2 weeks.

---

Procedural Requirements and Restrictions

The anal region must be thoroughly cleansed before application, and administration is advised after defecation. For internal use of the cream, a supplied applicator is screwed onto the tube and used for proper delivery. If a dose is missed, the application continues as normal at the next prescribed time and the amount is not doubled. Furthermore, this medicine is not recommended for use in children below 18 years of age due to a lack of available data on safety and efficacy.

Research evidence / Overview of studies for Doloproct 0.1% + 2%

Evidence for Acute Symptom Management in Hemorrhoidal Disease

The research base for the fluocortolone and lidocaine combination was used in research exploring how symptoms change over time related to hemorrhoidal disease. Studies have been conducted during periods of increased symptom activity, focusing on episodes where symptoms become more noticeable. The available research includes large-scale prospective non-interventional cohort studies, which involve observing how a group of patients fares over a defined time.

Research examined outcomes related to physical discomfort, tracking patient-reported severity scores for localized pain, itching (pruritus), burning, and swelling. Studies also monitored objective measures, such as changes in the size of hemorrhoidal nodes. Findings indicate patterns related to short-term changes in these tracked outcomes measured during the study period. The majority of this evidence is derived from studies involving adults with lower-grade hemorrhoidal disease (Stage 1 or 2).

Research Context for Supportive Use After Anorectal Procedures

The combination medicine was evaluated in specific short-term research scenarios, such as exploring pain patterns in the immediate aftermath of hemorrhoid removal surgery (hemorrhoidectomy). Controlled trials monitored the intensity of post-operative pain over very short follow-up periods, typically lasting less than seven days. The available data show patterns related to how pain was reported in the study groups during this acute phase.

Uncertainty, Long-Term Data, and Specific Populations

The certainty around the evidence remains limited due to several factors, including a reliance on large observational research for the specific combination. Follow-up durations were limited to the short-term acute treatment phase, extending up to 14 days. This constraint means long-term effects are not fully established, and there is limited information regarding recurrence rates or durability of symptomatic change.

The research results apply only to the populations studied. Data for certain groups remain insufficient, including patients with higher-grade disease (Stage 3 or 4), children, pregnant or breastfeeding individuals, or patients with concurrent complex conditions.

Key Studies & References

1. The effectiveness of combined topical product with fluocortolone pivalate and lidocaine for hemorrhoids: results of a multicenter observational study
2. A Systematic Review of the Topical Drugs for Post Hemorrhoidectomy Pain

Common questions about Doloproct 0.1% + 2% (FAQ)

---

Q: What is the main difference between the cream and the suppository forms of Doloproct 0.1% + 2%?

According to the official instructions, the cream formulation is described for use on the external anal area and for internal application with a supplied applicator. The suppositories, conversely, are designed solely for internal administration. Both forms contain the same active ingredients, but their method of delivery differs based on the affected site.

---

Q: What specific conditions is Doloproct 0.1% + 2% officially indicated to treat?

Official product information states that this medicine is indicated for the symptomatic relief of localized discomfort. These authorized therapeutic indications specifically include hemorrhoids, non-infective proctitis (inflammation of the rectum), and perianal eczema. It addresses symptoms like pain, swelling, burning, and itching associated with these conditions.

---

Q: How quickly does the pain relief or numbing effect usually begin after applying the medicine?

The numbing effect is achieved by the Lidocaine component, which acts by blocking nerve signals directly at the site of application. This mechanism is expected to result in a rapid onset of local relief. While official documents describe the intended fast action, they typically do not provide a specific time-to-onset measured in minutes.

---

Q: Is Doloproct 0.1% + 2% available only by prescription or can it be bought over-the-counter?

The regulatory status of the medicine, which determines its availability, differs by country. Official regulatory documents classify the medicine as either a Prescription Only Medicine (POM) or a pharmacy medicine (P). This classification describes whether the product is a Prescription Only Medicine or is available for purchase under pharmacist supervision.

---

Q: Is there a risk of skin thinning (atrophy) from using the corticosteroid in this medicine?

The safety profile for potent corticosteroids includes the potential for localized adverse reactions, such as skin atrophy (thinning). Regulatory guidance emphasizes that this risk is associated with the medicine being used for prolonged periods beyond the recommended course duration.

---

Q: Is it acceptable to use Doloproct 0.1% + 2% with other topical skin care products?

Regulatory documents do not specifically detail interactions with non-medicated topical skin care products. However, official warnings mention the need for careful consideration when using any concomitant topical treatment in the same area.

---

Q: What should I do if a small amount of the cream or suppository is swallowed accidentally?

Regulatory overdose information primarily focuses on the systemic effects of excessive topical use. However, if a substantial amount of the cream or suppository is accidentally ingested, official documents state that medical assistance should be sought immediately for guidance.

---

Q: What information is available regarding the use of Doloproct 0.1% + 2% while breastfeeding?

Regulatory documents describe the medicine's status during breastfeeding as permissible only when the clinical benefit of treatment is considered to outweigh the potential risk to the child. Additionally, official guidance states that application of the preparation to the breast area should be avoided.

---

Q: Can Doloproct 0.1% + 2% cause an allergic reaction, and what are the signs?

Hypersensitivity, which is the medical term for an allergic reaction, is listed in regulatory documents as a possible adverse reaction. This may appear as a localized skin reaction at the application site. Official guidance advises that treatment should be stopped immediately if any signs of skin irritation or an allergic reaction are noticed.

---

Q: Does the medicine contain petroleum jelly or any oil-based ingredients that might affect certain products?

Official warnings state that certain excipients (inactive ingredients) found in the formulation, such as hard fat and castor oil, may compromise the integrity of latex products. This means the effectiveness and safety of latex condoms or diaphragms may be reduced if they come into contact with the medicine.

---

Q: Do official labels discuss using this product for anal fissures or is it strictly for hemorrhoids?

Regulatory labeling generally restricts the authorized uses to hemorrhoids, non-infective proctitis, and perianal eczema. Anal fissures are typically not listed among the primary therapeutic indications in the official product information.

---

Q: Why is a high-potency steroid used for a sensitive area like the perianal region?

The product is designed as a fixed-dose combination to provide rapid relief from both pain and acute inflammation. The choice of a potent corticosteroid is related to its effective anti-inflammatory activity. Its use is limited to short durations, which keeps the potential for systemic absorption generally low when applied topically to the affected mucosa.

---

Q: What are the inactive ingredients or excipients contained in the cream formulation?

Official documents list the specific inactive ingredients, or excipients, contained in the cream formulation base. These typically include compounds such as hard fat, castor oil, macrogol, and purified water. These components help form the cream base and allow for the proper delivery of the active ingredients.

---

Q: Where can I find the official regulatory Patient Information Leaflet (PIL) for Doloproct 0.1% + 2%?

Official patient information leaflets and regulatory documentation are typically published by national regulatory authorities. You can generally locate this information by searching for the drug name on the respective government agency’s public portal (e.g., MHRA, EMA, FDA).

---

Q: Is there official guidance regarding the use of Doloproct 0.1% + 2% in the elderly population?

Official documentation confirms that no specific dose adjustment is generally necessary for patients in the elderly population. This is provided the individual does not have severe impairment of the liver (hepatic) or kidney (renal) function.

---

Q: Is it true that prolonged use can sometimes cause pigment changes in the skin?

Regulatory texts for potent corticosteroids note that local hypopigmentation (changes in skin color) is listed as a possible adverse reaction. This potential effect is generally associated with prolonged or extensive use that extends beyond the recommended time limit.

---

Q: Does the medicine lose its potency if it's not stored according to the official instructions?

Official storage conditions are carefully established to ensure the quality and efficacy of the product throughout its intended shelf life. Deviation from these instructions, such as exposure to excessive heat or freezing, may compromise the potency and integrity of the active ingredients.

How to Store and Dispose of Doloproct 0.1% + 2%

The official regulatory guidelines define strict storage and disposal requirements to ensure product stability and safety.

Storage Requirements

Doloproct rectal cream and suppositories must be stored at a controlled room temperature and not above 30°C (86°F). It is essential to protect the medicine from freezing, excessive heat, and direct light. The product should be kept in its original container and the tube must be tightly closed when not in use. After the tube is first opened, any remaining cream must be discarded within the labeled in-use period (e.g., typically four weeks).

Disposal Instructions

For safety, the medication must be kept out of the sight and reach of children. Expired or unused Doloproct must not be thrown away in household waste or poured down a drain. Patients must ask a pharmacist for instructions on how to properly dispose of the medicine according to local environmental regulations.